XClose

Centre for Amyloidosis and Acute Phase Proteins

Home
Menu

National Amyloidosis Centre

Head/Clinical Director
Professor Philip Hawkins 020 7433 2815/2816
     
Emeritus Professor/Consultant Professor Sir Mark Pepys 020 7433 2801/2802
     
Senior Lecturers/Readers/ Consultants Dr Marianna Fontana 020 7433 2764
  Dr Julian Gillmore
020 7433 2726
  Dr Helen Lachmann 020 7433 2804
  Dr Ashutosh Wechalekar 020 7433 2758
  Dr Carol Whelan 020 7433 2779
     
Clinical Fellows
Dr Shameem Mahmood 
020 7433 2770
  Dr Richa Manwani
020 7433 2733
  Dr Cristina Quarta
020 7433 2823
  Dr Tamer Rezk
020 7433 2823
  Dr Taryn Youngstein
020 7433 2763
     
Lead Nurse
Dr Thirusha Lane
020 7433 2759
     
Specialist/Research Nurses
Darren Foard 020 7433 2814
  Lisa Rannigan 020 7433 2732
  Rene Williams
020 7433 2797
     
Clinic Coordinator
Eleanor Pyart
020 7433 2738
     
Clinic Nurse
Charlene Kearney
020 7433 2799
     
Appointments &
Office Manager

Ramon Lamarca 020 7433 2813
     
Centre Administrator/Academic PA
Jean Berkeley
020 7433 2816
     
Unit Secretaries
  020 7433 2737/2798/2811
Transport & Accommodation
  020 7433 2812
General Enquiries
  020 7433 2725
Fax
  020 7433 2817


The NHS National Amyloidosis Centre is the only centre in the UK specialising in amyloidosis and is part of University College London Centre for Amyloidosis and Acute Phase Proteins, one of the world’s leading centres for amyloid research. The Centre has “state of the art” clinical and research facilities, and a team of highly qualified clinical, research and support staff.

We pioneered scintigraphic imaging (scanning) of amyloid as a quantitative diagnostic procedure and provide a comprehensive clinical service for patients with all types of acquired and hereditary systemic amyloidosis.  The NHS National Amyloidosis Centre is commissioned by NHS National Specialised Services and funded by the Department of Health to provide a diagnostic and management advice service for the UK’s national caseload of patients with amyloidosis and related disorders.  We have evaluated over 10,000 patients. The clinical service includes:

  • Detailed clinical assessment.
  • Diagnosis, quantification and monitoring of amyloidosis with whole body SAP scintigraphy.
  • Comprehensive expert diagnostic and monitoring studies of the heart, as required, by cardiac magnetic resonance, echocardiography and DPD scanning.
  • Review of diagnostic biopsies and specialised immunohistochemistry to determine amyloid type.
  • Characterisation and exclusion of hereditary amyloidosis by DNA testing; genetic counselling.
  • Measurement and monitoring of specialised biochemical (blood) tests for serum free light chains and serum amyloid A protein.
  • Recommendations for treatment and monitoring response.
  • 3‑12 monthly follow‑up to assess response and further treatment requirements. Sometimes follow‑up assessment can be performed by telephone if patients live far away.
  • Providing information and support to amyloidosis patients, their families and health providers.
  • Systematic evaluation of existing and new treatments.
  • Diagnosis, monitoring and treatment of inherited fever syndromes.